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Therapeutic eﬃcacy of an “Indigenous vaccine” has been evaluated with respect to a commercial vaccine (Gudair, Spain), for the
control of clinical Johne’s disease (JD) in naturally infected goatherds. Seventy-one goats (JD positive) were randomly divided into
3 groups (“Bison”, “Gudair” and “Sham-immunized”). After vaccination, goats were monitored for physical condition, morbidity,
mortality, body weights, shedding of M. paratuberculosis (MAP) in feces, internal condition and lesions, as well as humoral and
cell-mediated immune responses for 210 days. Study showed marked overall improvement in physical condition of vaccinated
goats and average body weight gain was signiﬁcantly higher (P<. 05) in “Bison” group as compared to “Sham-immunized” goats.
Mortality due to JD was signiﬁcantly (P<. 05) lower in vaccinated groups than in “sham-immunized”. Morbidity rates (due to
diarrhea and weakness) were lower in “Bison” group as compared to other groups. Died goats from vaccinated groups showed
regression of gross JD lesions and regeneration of fat layer around visceral organs while “Sham-immunized” goats exhibited frank
lesions. Vaccinated goats had higher protective CMI response and also higher antibody titer for the trial period as compared
to “Sham immunized”. Both vaccines also reduced shedding of MAP in feces signiﬁcantly (P<. 05). Though the two vaccines
eﬀectively restricted the severity of clinical symptoms of JD, however “Indigenous vaccine” was superior in many respects.
1.Introduction
Mycobacterium avium subspecies paratuberculosis (MAP) is
the cause of chronic incurable infection of animals called
Johne’s disease (JD) and is also associated with Crohn’s
disease (CD) in human beings [1]. MAP has wide host range
and interspecies transmission has been reported frequently
[2]. JD causes huge economic losses by way of reduced
productivity in domestic ruminants, all over the world. It is
estimated that 68.0% of US dairy herds are infected with JD,
costing $200 million to $1.5 billion per year to dairy industry
[3]. These losses have been neither estimated nor realized
in most of the developing and poor countries. In animals
vaccination is the only cost eﬀective method for controlling
JD. After the ﬁrst description of a live attenuated vaccine in
France [4], many of the developed countries resorted to vac-
cination and have eﬀectively decreased JD prevalence in their
h e r d sa n dﬂ o c k s[ 5–10]. Both killed and live attenuated vac-
cines have the same eﬃciency in small ruminants [11]; how-
ever, killed vaccine has many advantages in terms of safety,
marketing,andstorage[12].Vaccinepreparedfromﬁeldiso-
late worked better than “commercial vaccine” in calves [13].
Goatherds maintained at Central Institute for Research
on Goats (CIRG), Makhdoom were endemic for JD [14–
16].Using “test-and-cull”policy forpast 25 years,prevalence
of JD could not be reduced. Contrarily the incidence and2 Veterinary Medicine International
pathogenicity of MAP increased over the years [14, 15].
Native “S 5” strain of MAP [17] recovered from a terminally
sick goat has been characterized as “Indian Bison type”
[18] and is most prevalent genotype in India [19]. This
native “S 5” strain is highly pathogenic and is a newly
evolved genotype as compared to MAP K10 strain [20, 21],
therefore, used for the development of ELISA kit [16]a n d
“Indigenous vaccine” for JD [22]. This pilot study was the
ﬁrst randomized trial to know the eﬃcacy of “Indigenous
vaccine” in comparison to a “commercial vaccine” for
the control of Johne’s disease in clinically infected farm
goatherds.
2.MaterialsandMethods
2.1. Animal Ethics. Institute (CIRG) is registered with
Committee for the Purpose of Control and Supervision of
Experimentation on Animals (CPCSEA), Government of
India, and use of JD-infected goats was approved by the
Institute Ethics Committee.
2.2. Animals and Management Conditions. Seventy-one dis-
carded ready to cull (stunted/weak/diarrheic) and naturally
infected goats with clinical JD (positive in culture and
ELISA) from the farm herds of CIRG were randomly divided
into 3 groups: “Bison”, “Gudair” and “Sham immunized”,
consisting of 29, 24, and 18 goats, respectively. This pilot
trial to study the eﬃcacy of “Indigenous vaccine” was truly
random, with respect to age, sex, and breed, stage of disease,
and body weights of goats. In each group, age of goats varied
from 1 to 8.2 years (85.0% were between 2–4 years). Goats
in 3 groups were maintained together under semiintensive
system of management with 150 gr of concentrate per goat,
irrespectiveofsex,age,bodyweight,andphysiologicalstatus.
Physically goats were weak and emaciated when transferred
from diﬀerent goats units at CIRG, and JD, being endemic
in goats, was primarily responsible for poor health condition
of goats [14, 15]. Skin was rough, hard, and dry, eyes were
dull and depressed, body weights were below normal, and
JD was major cause of morbidity, mortality, and culling of
goats.
2.3. Vaccines. Two inactivated vaccines: “indigenous vac-
cine” [22] developed using novel, native, pathogenic, and
genetically characterized “S 5” strain of MAP (Indian Bison
t y p e )o fg o a to r i g i n[ 20] and a “Commercial vaccine”
(Gudair) manufactured by CZ Veterinaria, Spain [23]
were compared for their therapeutic attributes (immune
response and improvement in the health status) of natu-
rally infected goats with clinical JD for a period of 210
days. “Indigenous vaccine” [22] contained 2.5mg (dried
weight) of heat inactivated native strain of MAP [20]w i t h
0.01% of Thiomersal suspended in Aluminum hydroox-
ide gel (CZ Veterinaria, Spain). Dry weight of 2.5 mg
contained approximately 12 × 108 bacilli per mL (McFar-
land standard). “Commercial” vaccine contained 2.5mg of
MAP bacilli (strain 316F) per mL of vaccine in mineral
oil.
2.4. Vaccination. Goats in “Bison” group were vaccinated
with 1mL of “indigenous vaccine” subcutaneously (behind
the ear). Similarly “Gudair” group was vaccinated with 1mL
of“Commercialvaccine”and“Sham-immunized”groupwas
given 1mL of sterilized PBS.
2.5. Data Recordings and Collection of Samples. Body weights
of the goats were recorded, zero day post vaccination (DPV)
and at 30DPV intervals up to 210 days. Average gain in
body weights by goats of three groups was analyzed using
ANOVA. Serum samples of all the goats and blood samples
of 9 goats (3 from each group) were screened by ELISA and
Lymphocyte Transformation Test (LTT), respectively. Nitric
oxide (NO) estimation was performed on serum samples
of all the goats at 30-day interval. Improvements in body
condition, mortality, and morbidity were recorded. Goats
that died during the trial period were subjected to detailed
necropsy and lesions were recorded. Goats falling sick were
treated symptomatically.
2.6. Peripheral Blood Mononuclear Cells (PBMCs). PBMCs
were isolated as per method of Boyum [24], using
Histopaque (Sigma-Aldrich).
2.7. Lymphocyte Transformation Test (LTT). LTT was per-
formed as per Uma et al. [25], with modiﬁcations, on the
representative goats (3 each) of the 3 groups (2 vaccinated
and 1 Sham immunized) using PBMCs at 60DPV. Brieﬂy,
PBMCs isolated from goats of each group were stimulated
in triplicate with mitogen Con A (Sigma) and sonicated
protoplasmic antigen of MAP “Indian Bison Type” each at
20μg/mLconcentration,andasetofPBMCsofthesamegoat
was kept as unstimulated control. PBMCs were cultured in
96-well tissue culture plates at 37
◦Ca t5 %C O 2 for 120 hours
(5 days). At the end of 120 hours MTT assay was performed
and 25μl of MTT [3-(4, 5- dimethyl trizol-2-yl)-2, 5-
diphenyl tetrazolium bromide] dye (5mg/mL) was added
to each well of the tissue culture plate. Plate was incubated
at 37
◦C for 4 hours. After incubation 150μlo fD M S O
(dimethyl sulfoxide) was added to each well and incubated
overnight at 37
◦C and absorbance was read at 570nm.
Proliferation of lymphocytes was indicated by optical density
value of the well with test samples and that of the unpulsed
wells. For analysis of data, a signal-to-noise ratio, that is,
Stimulative Index (SI) was calculated for individual goats
using the following formula: A v e r a g eO Da t5 7 0 n mi n
stimulated wells/Average OD at 570nm in nonstimulated
control wells. Average SI value for each group of goats was
calculated and compared to assess cellular immune response
in vaccinated and sham-immunized groups at 60DPV.
2.8. Enzyme Linked Immunosorbent Assay (ELISA). Pre- and
post-vaccination antibody response was measured by ELISA.
Antibody titers were monitored in all the goats from zero to
210DPVat30-dayintervalasperSinghetal.[16].ODvalues
of serum samples were transformed to S/P ratio as described
by Collins [26] and goats in strong positive category were
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2.9. Nitric Oxide (NO) Estimation. Nitric Oxide was esti-
mated at 0, 15, 45, 90 and each 30DPV after 90 days up
to 210DPV in the serum samples as per Sastry et al. [27].
Opticaldensity(OD)valuesweretransformedintoODindex
values by division of the mean OD for each serum by the
mean OD for the positive control.
2.10. Fecal Culture. Fecal culture was performed on zero and
210DPVfromallthegoatstochecktheeﬃciencyoftwovac-
cines in decreasing number of MAP shedders. Fecal samples
weregrounded,centrifuged,aswellasdecontaminated(0.9%
HPC), and sediment was inoculated on Herrold’s egg yolk
medium with mycobactin J as per Merkal [28].
3. Results
3.1.BodyConditions. Therewasmarkedimprovementinthe
overall body conditions of vaccinated goats as compared to
sham immunized. Vaccinated and Sham-immunized goats
could be easily diﬀerentiated from distance on the basis of
diﬀerences in the body conditions. Vaccinated goats were
alert, active, healthy, regained skin luster, shining, pliability,
regeneration of hairs and had shining bright eyes.
3.1.1. Body Weights. Average body weights, at the time of
vaccination in 3 groups, were almost similar (Table 1). At
the 210DPV there was signiﬁcant diﬀerence in the average
body weights gained by the goats of vaccinated groups than
in sham-immunized group. Goats in “Bison” group gained
higher body weights as compared to “Gudair” (P>. 05) and
“sham-immunized” (P<. 05) groups. Few goats from each
group lost weight (in comparison to weight at zero DPV)
during the trial period. Percentage of goats loosing body
weight was higher in sham-immunized (38.9%) followed
by Gudair (33.3%) and Bison (17.2%) groups. Lowered
number of vaccinated goats that lost weight after vaccination
was indicative of the maximum “individual eﬀect” of the
“Indigenous vaccine”.
3.1.2. Mortality Rates and Causes of Deaths. Overall mor-
tality rate was lower in vaccinated groups than in “Sham-
immunized” group (Table 2). Percent of goats that died due
to JD were 71.4%, 14.2%, and 16.6% in “sham-immunized”,
“Gudair”, and “Bison” groups, respectively. On comparing
the mortality due to JD between zero and 210 DPV, there
were signiﬁcantly less (X2 = 6.28, df = 1, P<. 02) deaths in
the vaccinated groups than in sham-immunized goats.
3.1.3. Morbidity Rate
3.1.4. Mortality Rates and Causes of Deaths. Overall mor-
tality rate was lower in vaccinated groups than in “Sham-
immunized” group (Table 2). Percent of goats that died due
to JD were 71.4%, 14.2%, and 16.6% in “sham-immunized”,
“Gudair”, and “Bison” groups, respectively. On comparing
the mortality due to JD between zero and 210 DPV, there
were signiﬁcantly less (X2 = 6.28, df = 1, P<. 02) deaths in
the vaccinated groups than in sham-immunized goats.
3.1.5. Morbidity Rate. There was minor outbreak of con-
tagious ecthyma (Orf) in 12 vaccinated goats just after
vaccination and lasted for 7 days. In “Bison” group, one goat
of Marwari breed suﬀered from maggotic wound and was
under treatment for 22 days. There was signiﬁcant decrease
in the body weight of this goat. In “sham-immunized” group
besides diarrhea, pneumonia was frequent cause of sickness.
Number of goats sick (due to diarrhea and weakness)
and those that received treatment during trial period were
higherinsham-immunizedgroupascomparedtovaccinated
groups.
3.1.6. Gross Lesions of JD at Necropsy. Four goats, out of 7
died in “Sham-immunized group”, had marked gross lesions
of JD, and typical acid fast bacilli indistinguishable from
MAP were demonstrated in impression smears. Whereas,
2 goats that died at 60 DPV in “Gudair” group showed
mildre inﬂammatory lesions in mesenteric lymph nodes
(reduced thickening and size, lowered level of inﬂammation)
and intestines (lowered thickening and no corrugations).
Substantial fat layer was generation around all the visceral
organs as compared to goats that died in sham-immunized
group. Similarly, in “Bison” group also gross lesions of
JD were mild in goats that died within few months of
vaccination. Marked improvements were seen in the internal
condition of one goat of “Bison” group that died at 165DPV.
Wherein gross lesions for JD were very mild, carcass yield
was average and there was extensive regeneration of fat
layer (visceral fat, kidney fat, cod fat, fat on genital organs,
etc.) around all the visceral organs in comparison to sham-
immunized goats (Figure 1). This goat died of acidosis.
3.2. Cellular Immune Response (CMI)
3.2.1. Lymphocytes Transformation Test (LTT). Ability of
the PBMCs to recognize and respond to MAP antigen
was investigated. PBMCs of vaccinated groups had greater,
“Stimulative Index” (SI), when pulsed with protoplasmic
antigen from native MAP strain than “Sham-immunized”
group at 60DPV (Figure 2). However, SI was higher in
“Bison” as compared to “Gudair” group. Proliferation of
cells in response to mitogen was higher as compared to
stimulation with MAP in all the three groups.
3.2.2. Nitric Oxide Estimation. Results of nitric oxide (NO)
production were expressed as geometric means at each
sampling interval and are graphically presented in Figure 3.
At 0DPV, concentration of NO in serum was comparable
among the 3 groups, but afterwards vaccinated group of
goats had higher NO concentration than “sham immunized”
(Figure 3). At 45DPV and onward sampling intervals, both
of the vaccinated groups had signiﬁcantly higher (P<. 05)
concentration of NO as compared to “sham-immunized”
group. In “Bison” and “Gudair” groups, peak NO concen-
tration was seen at 45DPV and subsequently concentration
declined slightly at 90DPV. After 90DPV at each sampling4 Veterinary Medicine International
Table 1: Average body weights gained per goat, by vaccinated and “Sham-immunized” groups.
Groups Average body weights (kg) Average body weights gained/goat (kg)
± SE at 0 DPV∗ ± SE (0DPV–210DPV)
Bison 23.65 ±0.67 5.49 ±1.04
Gudair 24.10 ±0.54 2.75 ±0.89
Sham immunized 23.05 ±0.50 1.23 ±1.15
∗DPV: Days post vaccination.
Vaccinated group Sham-immunized group
Mesenteric lymph node
Intestine part at ileocaecal region
Omental fat
Figure 1: Pictorial presentation for comparative gross lesions (in mesenteric lymph nodes and intestines) and presence of omental fat in
vaccinated and sham-immunized goats.
interval, goats in vaccinated groups maintained NO concen-
tration with slight up and down and remained higher than
sham-immunized goats at all the postvaccination intervals.
3.3. Humoral Immune Response (ELISA). After vaccination
high seroconversion rates were seen in vaccinated goats
as compared to “Sham-immunized” (Figure 4). Number of
goats were positive in ELISA test at the time of vaccination
(0DPV), since the trial was conducted on discarded goats
with advanced stage of MAP infection. However, percent
goats seroconverted remained higher in vaccinated groups
than in “Sham-immunized” group at all the postvaccination
sampling intervals. Almost all the goats in vaccinated groups
became seropositive (seroconverted) at 150DPV (Figure 3).
3.4. Fecal Culture. F e c a lc u l t u r eo fg o a t si n3g r o u p sw a s
performed at zero and 210DPV. Percent of goats positive
for MAP at 0 day were 88.8, 79.3, and 79.1 in “sham-
immunized”, “Bison”, and “Gudair” groups, respectively. At
210DPV there was signiﬁcant reduction in shedding of MAP
(Bison: X2 = 4.293, P = .038; Gudair: X2 = 3.938, P =
.047) in feces of goats in “Bison” and “Gudair” groups. Two
vaccines reduced shedding of MAP in feces dramatically and
only 17.2 and 29.1% goats were excreting MAP in “Bison”
and “Gudair” groups, respectively, at 210DPV. In “sham-
immunized” group, all the goats (18 = 100%) were positive
for excretion of MAP at 210DPV.
4. Discussion
Vaccination has been known to oﬀer good protection and
recovery against MAP infection and shown to reduce the
prevalence of clinical JD by 90% and prevalence of JD
in herds by about 50% [29]. First Indian “Indigenous
vaccine” against JD in goats [22] was developed using
most prevalent and highly pathogenic “S 5” strain of
Mycobacterium avium subspecies paratuberculosis (MAP)
genotypedas“IndianBisonType”.This“indigenousvaccine”
has been shown to provide good protection (prophylactic)Veterinary Medicine International 5
Table 2: Mortality rates and causes of deaths during vaccination
trial.
Causes of deaths “Sham immunized” “Bison” “Gudair”
Other than JD∗ 26 5
(28.6) (85.7) (83.3)
Johne’s Disease 51 1
(71.4) (14.2) (16.6)
Goats died/total 51 1
(Mortality rates) (38.9) (24.1) (25.0)
Causes of deaths other than JD∗: Pneumonia/Haemonchous/weakness/
Acidosis; Figures in parentheses are percent.
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Figure 2: Comparison of Cellular Immune response (Stimulation
Index) in two vaccine groups and a sham-immunized group at 60
days post vaccination.
in experimentally vaccinated and twice-challenged goats
[22]. There are a number of reports on the prophylactic
properties of JD vaccine, whereas very few reports are
available on the therapeutic potential. Substantial reports
exist on the signiﬁcant reduction in mortality, clinical
symptoms, and excretion of MAP bacilli in feces after vac-
cination of infected goats, thereby reducing environmental
contamination and providing less opportunity for disease
transmission.
Sigurdsson and Gunnarson [10] achieved successful
eradication of JD in Iceland by vaccinating lambs once with
killed vaccine. Similar results were reported by Crowther et
al. [6] in sheep in Cyprus by vaccinating all stocks with live
attenuated vaccine. Similarly in Norway, after several years
of unsuccessful eﬀorts to eradicate JD in goats (isolation
and slaughter), vaccination program with “live attenuated
vaccine” for kids was started in 1967 and the infection of
MAP was reduced from 53% to 1% [30]. In 1964, Great
Britain introduced a scheme for the voluntary vaccination of
thestockoninfectedfarmsandfreedomfromclinicaldisease
was achieved after an average of 4 years [31]. In 1983, a
control program based on killed vaccine was initiated in The
Netherlands and this strategy has been successful in reducing
clinical JD and was less expensive than subsidized cull and
slaughter program [7].
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Results of the present study also indicated that vac-
cination could be practiced in any stage of disease (sub-
clinical, clinical, and advance clinical), in any agegroup (kids
above 3 months old to adults) and in any physiological stage
(dry, lactating, or pregnant). Initial priming of the goats
with MAP infection at the start of trial could have elicited
higherimmuneresponseagainstvaccine(secondinoculation
of the antigen). JD was endemic in CIRG herds; therefore,
continuous and slow reinfection of vaccinated animals from
environment might have booster eﬀect, thereby complete
turnaround in the condition of ready to cull goats when trial
was started. Incomplete degree of the response in 15-day-
old kids as observed by Corpa et al. [32] might be due to
immature immune system at that age. JD vaccination has
been practiced during ﬁrst weeks of life on the basis that
the protection would be conferred for the ﬁrst contact with
mycobacteria [30,33].However,otherstudiesonvaccination
of adult animals also showed very good results in controlling
JD[6,9].Corpaetal.[32]alsoshowedthatimmuneresponse
was higher in adult animals as compared to few weeks old
animals.
Lymphoproliferative response to antigen stimulation has
been widely used as in vitro correlates of cell-mediated6 Veterinary Medicine International
immunity [34]. PBMCs from vaccinated and “sham-
immunized” goats were used to assess the response to
protoplasmic antigen of MAP. Proliferative response was
higher in PBMCs from vaccinated groups on stimulation
with MAP antigen than in PBMCs from “sham-immunized”
group. However, stimulative index was higher in PBMCs
from “Bison” than in “Gudair” group. Low responsiveness
may be attributed to the suppressive factors secreted by
monocytes and lymphocytes [35]. Another possibility may
be a shift from Th l to Th 2 type of cytokine response [36].
Further preferential sequestration of antigen-speciﬁc T cells
into the infected areas leads to their absence in peripheral
blood [37].
It is generally believed that reactive nitrogens, such as
NO, are most eﬀective in direct killing of mycobacteria [38].
SigniﬁcantlyhigherNOconcentrationwasseeninvaccinated
groups (maximum in “Bison” group and least for “sham-
immunized”group).IncreasedproductionofNOinducedby
antigen may cause eﬀective immune response towards MAP
and may lead to inhibition of MAP in macrophages.
Signiﬁcant rise in the peripheral blood antibodies was
seen in vaccinated groups after vaccination and “peak titers”
were attained at 60DPV that gradually declined, such pat-
tern was absent in “sham-immunized” group. Comparative
antibody titers, in the vaccinated groups, were higher in
“Bison” group. In vaccination of sheep by a killed vaccine
maximum ELISA reactors were observed around 30DPV
[39]. In a study, 13 of the 15 vaccinated calves also became
ELISA positive within 60 to 360DPV [40]. In some goats of
vaccinated group there was again rise in the antibody titer
at 180DPV. But this rise in the antibody titer was less than
the primary maxima observed at 60DPV. Although antibody
response may not have the protective eﬀect, it would be
an indicator of the degree of the activation of immune
systemagainstmycobacteria[32].Th1andTh2responsesare
not antagonist and IFNγ can play stimulatory eﬀect on B-
lymphocytes and antibody production [41]. Antibody titers
were higher in few goats of “sham-immunized” group but
titers were low as compared to vaccinated groups.
There was decreasing trend of NO concentration in
“sham-immunized” goats. Probably protective Th1 response
decreased due to decrease in the concentration of pro-
inﬂammatory cytokines (IFNγ, IL-12, IL-2, TNFα,e t c . ) .
Though NO concentration also showed decreasing trend
in vaccinated goats, they still maintained signiﬁcantly
higher concentration of NO as compared to “sham-
immunized” goats. These results were further supported by
antibody results, in “sham-immunized” goats, where titers
increased slightly towards the end of the experiment. As
“‘sham-immunized” goats approached terminal stage of JD,
inhibitoryTh2responsesmightbeincreasedwithsuppressed
activityofantiinﬂammatorycytokinestolimitthehosttissue
damage.
Necropsyofgoatsfrom“sham-immunized”groupexhib-
ited marked gross lesions of JD. Lymph nodes were highly
enlarged and swollen, intestinal mucosa was thickened with
prominentridges(corrugation),anddegenerationofvisceral
fat was marked in these goats. Goats from vaccinated groups
did not show severe lesion of JD grossly due to remission
of lesions after vaccination. In a study of vaccination in
infected animals, Corpa et al. [32] also reported reduction
in progression of granulomatous lesions and in bacterial
shedding. Similarly, Juste et al. [42] also noticed regressive
type granulomas (tuberculoid forms of lesions) located
exclusively in the intestinal organized lymphoid tissues
in vaccinated animals, whereas in nonvaccinated animals
lesions spread to other areas of intestine causing severe
enteritis. Therefore, vaccination may have potential to direct
the inﬂammatory cascade into a beneﬁcial mode.
Vaccinationreducedfecalsheddinginsigniﬁcantnumber
of vaccinated goats. Initially, 16 (88.8%) goats were positive
in “sham-immunized” group, but at 210DPV all the goats
were positive in fecal culture. At zero and 210DPV, the
number of goats excreting MAP decreased from 23 (79.3%)
and 19 (79.1%) to 5 (17.2%) and 7 (29.1%) in “Bison” and
“Gudair” groups, respectively. Number of goats negative for
MAPinfection weremore in “Bison” group. Colony-forming
units (cfu) counts also decreased in vaccinated goats as
compared to 0 DPV. However, in “sham-immunized” group,
cfu increased in 55.0% of goats.
Vaccination of lambs against ovine JD reduced deaths
up to 90% and also reduced amount of bacilli passed in
feces by up to 90% [8]. Rapid decrease in new clinical cases
wasachievedfollowingimmunizationofinfectedadultsheep
ﬂocks having severe clinical disease [9]. Similar results have
been reported by Uzonna et al. [13], where vaccine prepared
from ﬁeld isolate reduced the number of fecal shedders more
than that of commercial vaccine.
Present trial indicated that “Indigenous vaccine” used
in this study exhibited “Therapeutic eﬀect” by reversing the
clinical signs. There was reduction in shedding of number
of MAP bacilli per goat, number of goats with clinical,
JD and number of goats positive bacteriologically (fecal
shedders), and complete turnaround was visible in the
physical condition of the vaccinated goats as compared to
“sham immunized”. Internally the lesions of JD reduced and
there was regeneration of visceral fat layer and fat layer
around all the visceral organs. Goat became alert active, and
udders were ﬁlled with milk despite continuous suckling by
kids. “Indigenous vaccine” using aluminum hydrooxide gel
as adjuvant was superior to “Gudair” using mineral oil, in
controlling JD in the naturally infected goats. However, these
minor diﬀerences in vaccine-induced immune response
may have resulted due to use of two diﬀerent adjuvants,
diﬀerences in the genetic makeup of individual animals and
level of MAP infection.
5. Conclusions
Single dose of “Indigenous vaccine” developed from highly
pathogenic locally isolated “Indian Bison Type” genotype of
MAPsigniﬁcantlyreducedmorbidityandmortality,reversed
clinical signs as well as reduced shedding of MAP, and
there was marked improvement in physical and internal
body condition (Therapeutic eﬀect). Therefore, “Indigenous
vaccine” worked as “Therapeutic Vaccine” in goats suﬀering
from clinical to advance clinical symptoms of JD.Veterinary Medicine International 7
Abbreviations
MAP: Mycobacterium avium subspecies
paratuberculosis
JD: Johne’s disease
LTT: Lymphocyte transformation test
NO: Nitric Oxide
MTT: 3-(4, 5-dimethyl trizol-2-yl)-2,
5-diphenyl tetrazolium bromide
DMSO: dimethyl sulfoxide
CMI response: Cell-mediated immune response
ELISA: Enzyme-linked immunosorbent
assay
cfu: Colony-forming unit
SI: Stimulative index
OD: Optical density,
DPV: Days post vaccination
gr: Gram.
Acknowledgment
Authors are thankful to Director, CIRG, for extending
necessary facilities for the work and DSIR, New Delhi for
providing ﬁnancial assistance.
References
[1] R. J. Chiodini, H. J. Van Kruiningen, R. S. Merkal, W. R.
Thayer, and J. A. Coutu, “Characteristics of an unclassiﬁed
Mycobacterium species isolated from patients with Crohn’s
disease,” Journal of Clinical Microbiology,v o l .2 0 ,n o .5 ,p p .
966–971, 1984.
[ 2 ]W .Y .A y e l e ,M .M a c h´ ackov´ a, and I. Pavl´ ık, “The transmission
and impact of paratuberculosis infection in domestic and wild
ruminants,” Veterinarni Medicina, vol. 46, no. 7-8, pp. 205–
224, 2001.
[ 3 ]S .L .O t t ,S .J .W e l l s ,a n dB .A .W a g n e r ,“ H e r d - l e v e le c o n o m i c
losses associated with Johne’s disease on US dairy operations,”
Preventive Veterinary Medicine, vol. 40, no. 3-4, pp. 179–192,
1999.
[4] H. Valle´ e, P. Rinjard, and M. Valle´ e, “Sur la pr´ emunition de
l’enterite paratuberculeuse des bovides,” Revue G´ en´ erale De
M´ edecine V´ et´ erinaire, vol. 43, pp. 777–779, 1934.
[5] G. Benedictus, “Evaluation of the organized control of
paratuberculosis in the province of Friesland,” Tijdschrift voor
Diergeneeskunde, vol. 109, no. 22, pp. 905–916, 1984.
[6] R. W. Crowther, K. Polydorou, S. Nitti, and A. Phyrilla,
“Johne’s disease in sheep in Cyprus,” Veterinary Record, vol.
98, no. 23, p. 463, 1976.
[ 7 ]A .A .D i j k h u i z e n ,G .V .S c h a i k ,R .M .B .H u i r n e ,C .H .J .
Kalis, and G. Benedictus, “Cost beneﬁt analysis of vaccination
against paratuberculosis in dairy cattle,” Kenya Veterinarian,
vol. 18, pp. 219–221, 1994.
[8] “Meat and livestock Australia (MLA),” North Sydney, NSW,
Australia, 2005.
[9] V. Perez, J. F. Garcia Marin, R. Bru, B. Moreno, and J. J.
Badiola, “Results of vaccination of adult animals against ovine
paratuberculosis,” Medicina Veterinaria, vol. 12, no. 3, pp.
196–201, 1995.
[10] S. Sigurdsson and E. Gunnarson, “Paratuberculosis in sheep,
goats and reindeer in Iceland: a result of an import of a
ﬂock of sheep from Germany 1933. The control of dis-
ease,” in Proceedings of the 1st International Colloquium on
Paratuberculosis (ICP ’83), pp. 239–244, Aures, Iowa, USA,
1983.
[11] J. F. Garcia Marin, J. Tellechea, M. Gutierrez, J. M. Corpa, and
V. Perez, “Evaluation of two vaccines (killed and attenuated)
against small ruminant paratuberculosis,” in Proceedings of the
6thInternationalColloquiumonParatuberculosis(ICP’99),p p .
236–241, Melbourne, Australia, 1999.
[12] H. Huitema, “Johne’s disease in cattle and vaccination,”
Bulletin de l’Oﬃce International des Epizooties, vol. 68, no. 1,
pp. 743–748, 1967.
[13] J. E. Uzonna, P. Chilton, R. H. Whitlock, P. L. Habecker,
P. Scott, and R. W. Sweeney, “Eﬃcacy of commercial and
ﬁeld-strain Mycobacterium paratuberculosis vaccinations with
recombinant IL-12in a bovine experimental infection model,”
Vaccine, vol. 21, no. 23, pp. 3101–3109, 2003.
[14] P. Kumar, S. V. Singh, A. K. Bhatiya, et al., “Juvenile Capri-
Paratuberculosis (JCP) in India: incidence and characteriza-
tion by six diagnostic tests,” Small Ruminant Research, vol. 73,
no. 1–3, pp. 45–53, 2007.
[15] S. Kumar, S. V. Singh, I. Sevilla, et al., “Lacto-incidence and
evaluation of 3 tests for the diagnosis of Johne’s disease
using milk of naturally infected goatherds and genotyping
of Mycobacterium avium subspecies paratuberculosis,” Small
Ruminant Research, vol. 74, no. 1–3, pp. 37–44, 2008.
[16] S. V. Singh, A. V. Singh, P. K. Singh, V. K. Gupta, S.
Kumar, and J. Vohra, “Sero-prevalence of paratuberculosis in
young kids using ‘Bison type’, Mycobacterium avium subsp.
paratuberculosis a n t i g e ni np l a t eE L I S A , ”Small Ruminant
Research, vol. 70, no. 2-3, pp. 89–92, 2007.
[17] S. Hajra, S. V. Singh, and A. K. Srivastav, “Pathobiology of
spontaneous and experimental paratuberculosis (S-5 strain)
in goats with special reference to early lesions,” in Proceedings
of the 8th International Colloquium on Paratuberculosis (ICP
’05), S. S. Neilsen, Ed., p. 152, Copenhagen, Denmark, August
2005.
[18] I.Sevilla,S.V.Singh,J.M.Garrido,etal.,“Moleculartypingof
Paratuberculosisstrainsfromdiﬀerenthostsandregions,”OIE
Revue Scientiﬁque et Technique, vol. 24, no. 3, pp. 1061–1066,
2005.
[19] S. V. Singh, J. S. Sohal, P. K. Singh, and A. V. Singh, “Genotype
proﬁles of Mycobacterium avium subspecies paratuberculosis
isolatesrecovered fromanimals,commercial milk,andhuman
beings in North India,” International Journal of Infectious
Diseases, vol. 13, no. 5, pp. e221–e227, 2009.
[20] J. S. Sohal, N. Sheoran, K. Narayanasamy, V. Brahmachari, S.
V. Singh, and S. Subodh, “Genomic analysis of local isolate of
Mycobacterium avium subspecies paratuberculosis,” Veterinary
Microbiology, vol. 134, no. 3-4, pp. 375–382, 2009.
[21] J. S. Sohal, S. V. Singh, P. K. Singh, and A. V. Singh, “On
the evolution of ‘Indian Bison type’ strains of Mycobacterium
avium subspecies paratuberculosis,” Microbiological Research,
vol. 165, no. 2, pp. 163–171, 2010.
[22] S.V.Singh,P.K.Singh,A.V.Singh,J.S.Sohal,andV.K.Gupta,
“Comparative eﬃcacy of an indigenous ‘inactivated vaccine’
using highly pathogenic ﬁeld strain of Mycobacterium avium
subspecies paratuberculosis ‘Bison type’ with a commercial
vaccine for the control of Capri-paratuberculosis in India,”
Vaccine, vol. 25, no. 41, pp. 7102–7110, 2007.8 Veterinary Medicine International
[23] A. Britton, “Safety and eﬃcacy assessments of killed mycobac-
terial vaccine-GudairTM for use in the control of ovine Johne’s
disease,” in Proceedings of the Australian Sheep Veterinary
Society Conference, pp. 207–214, Perth, Wash, USA, 2000.
[24] A. B¨ oyum, “Separation of leukocytes from blood and bone
marrow,” Scandinavian Journal of Clinical and Laboratory
Investigation, vol. 21, pp. 77–79, 1968.
[25] H. Uma, P. Selvaraj, A. M. Reetha, T. Xavier, R. Prabhakar,
and P. R. Narayanan, “Antibody and lymphocyte responses
to mycobacterium tuberculosis culture ﬁltrate antigens in
active and, quiescent (cured) pulmonary tuberculosis,” Indian
Journal of Tuberculosis, vol. 46, pp. 21–28, 1999.
[26] M. T. Collins, “Interpretation of a commercial bovine paratu-
berculosis enzyme-linked immunosorbent assay by using like-
lihoodratios,”ClinicalandDiagnosticLaboratoryImmunology,
vol. 9, no. 6, pp. 1367–1371, 2002.
[ 2 7 ]K .V .H .S a s t r y ,R .P .M o u d g a l ,J .M o h a n ,J .S .T y a g i ,a n dG .S .
Rao, “Spectrophotometric determination of serum nitrite and
nitrate by copper-cadmium alloy,” Analytical Biochemistry,
vol. 306, no. 1, pp. 79–82, 2002.
[28] R. S. Merkal, “Paratuberculosis: advances in cultural, sero-
logic, and vaccination methods,” Journal of the American
Veterinary Medical Association, vol. 184, no. 8, pp. 939–943,
1984.
[29] G. Lambert, “Paratuberculosis: prevalence, diagnosis, pre-
vention and treatment,” in Proceedings of the 17th Annual
ConventionofAmericanAssociationofBovinePractitioners,Des
Moines, Iowa, USA, July 1984.
[30] F. Saxegaard and F. H. Fodstad, “Control of paratuberculosis
(Johne’s disease) in goats by vaccination,” Veterinary Record,
vol. 116, no. 16, pp. 439–441, 1985.
[31] J. W. Wilesmith, “Johne’s disease: a retrospective study of
vaccinated herds in Great Britain,” British Veterinary Journal,
vol. 138, no. 4, pp. 321–331, 1982.
[32] J. M. Corpa, V. Pe´ erez, and J. F. Garc´ ıa Mar´ ın, “Diﬀerences
in the immune responses in lambs and kids vaccinated
against paratuberculosis, according to the age of vaccination,”
Veterinary Microbiology, vol. 77, no. 3-4, pp. 475–485, 2000.
[33] A. B. Larsen, W. W. Hawkins, and R. S. Merkal, “Experimental
vaccinationofsheepagainstJohne’sdisease,”AmericanJournal
of Veterinary Research, vol. 25, pp. 974–976, 1964.
[34] R. M. Pitchappan, V. Brahmajothi, K. Rajaram, P. T. Sub-
ramanyam, K. Balakrishnan, and R. Muthuveeralakshmi,
“Spectrum of immune reactivity to mycobacterial (BCG)
antigens in healthy hospital contacts in South India,” Tubercle,
vol. 72, no. 2, pp. 133–139, 1991.
[35] M. E. Kleinhenz and J. J. Ellner, “Antigen responsiveness
during tuberculosis: regulatory interactions of T cell subpop-
ulations and adherent cells,” Journal of Laboratory and Clinical
Medicine, vol. 110, no. 1, pp. 31–40, 1987.
[36] H. M. Surcel, M. T. Blomberg, S. Paulie, et al., “Th1/Th2 pro-
ﬁles in tuberculosis, based on the proliferation and cytokine
response of blood lymphocytes to mycobacterial antigens,”
Immunology, vol. 81, no. 2, pp. 171–176, 1994.
[37] G. A. Rossi, B. Balbi, and F. Manca, “Tuberculous pleural
eﬀusions. Evidence for selective presence of PPD-speciﬁc T-
lymphocytes at site of inﬂammation in the early phase of the
infection,” American Review of Respiratory Disease, vol. 136,
no. 3, pp. 575–579, 1987.
[ 3 8 ]J .M u l l e r a d ,A .H .H o v a v ,R .N a h a r y ,Y .F i s h m a n ,a n dH .
Bercovier, “Immunogenicity of a 16.7kDa Mycobacterium
paratuberculosis antigen,” Microbial Pathogenesis, vol. 34, no.
2, pp. 81–90, 2003.
[39] J. Eppleston, A. Britton, P. Windsor, D. Hall, R. Whittington,
and S. Jones, “Progress in a ﬁeld trial to determine the eﬀec-
tiveness of a killed Mycobacterium paratuberculosis vaccine for
the control of OJD in Australian sheep ﬂock,” in Proceedings of
the Australian Sheep Veterinary Society Conference, pp. 64–67,
Perth, Wash, USA, 2000.
[40] E. Spangler, L. E. Heider, S. Bech-Nielsen, and C. R. Dorn,
“Serologic enzyme-linked immunosorbent assay responses of
calves vaccinated with a killed Mycobacterium paratuberculosis
vaccine,” American Journal of Veterinary Research, vol. 52, no.
8, pp. 1197–1200, 1991.
[41] A. K. Abbas, K. M. Murphy, and A. Sher, “Functional diversity
of helper T lymphocytes,” Nature, vol. 383, no. 6603, pp. 787–
793, 1996.
[42] R. A. Juste, J. F. Garcia-Marin, B. Peris, C. S. de Ocariz,
and J. J. Badiola, “Experimental infection of vaccinated and
non-vaccinated lambs with Mycobacterium paratuberculosis,”
Journal of Comparative Pathology, vol. 110, no. 2, pp. 185–194,
1994.